-25.8%
TE vs MRNA
+945.0%
-970.8%
-82.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | +13.1% | -16.6% | -4.1% |
| 7D | +3.8% | +20.6% | -16.8% | +3.0% |
| 30D | -26.2% | +27.1% | -53.4% | -27.0% |
| 3M | -49.7% | +353.4% | -403.1% | -55.6% |
| 6M | -46.5% | +446.3% | -492.7% | -56.8% |
| YTD | -59.1% | +776.2% | -835.3% | -73.6% |
| 1Y | -25.8% | +987.9% | -1,013.7% | -55.2% |
| All | -25.8% | +945.0% | -970.8% | -55.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling